China Biologic Products Inc (CBPO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:China Biologic Products Inc (CBPO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9831
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
China Biologic Products Inc (China Biologic) is a biopharmaceutical company that offers plasma collection, research and development, production, commercialization of biopharmaceutical products and development of treatment products. The company manufactures, develops, and markets biologic products for the prevention and treatment of various diseases. Its plasma products include human albumin, human tetanus immunoglobulin, human rabies immunoglobulin, human immunoglobulin for intravenous injection, human hepatitis B immunoglobulin, thymopolypeptides injection, human immunoglobulin, and human coagulation factor VIII. China Biologic’s other product includes placenta polypeptide. The company provides services such as plasma collection, research and development, production, and commercialization of biopharmaceutical products. It offers products to hospitals and other healthcare facilities in China. China Biologic is headquartered in Beijing, China.

China Biologic Products Inc (CBPO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
China Biologic Products Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
China Biologic Products Inc, Medical Devices Deals, 2012 to YTD 2018 9
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
China Biologic Products to Raise USD590 Million in Private Placement of Shares 11
Consortium of Investors to Acquire Remaining Shares in China Biologic Products for USD3.9 Billion 13
CCRE Holdings to Acquire Remaining 94.9% Stake in China Biologic Products 15
Equity Offering 16
China Biologic Products Raises Funds through Public Offering of Shares 16
China Biologic Prices Public Offering of Shares for USD73.5 Million 18
China Biologic Prices Public Offering of Shares for USD30 Million 19
Acquisition 21
China Biologic Products Acquires Remaining 15.3% Stake in Guizhou Taibang Biological Products for USD62.5 Million 21
China Biologic Products Inc – Key Competitors 22
China Biologic Products Inc – Key Employees 23
China Biologic Products Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 01, 2018: China Biologic reports financial results for the third quarter of 2018 25
Aug 03, 2018: China Biologic reports financial results for the second quarter of 2018 31
May 04, 2018: China Biologic Reports Financial Results For First Quarter Of 2018 37
May 04, 2018: China Biologic Announces First Quarter 2018 Financial Results 40
Feb 28, 2018: China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2017 43
Nov 01, 2017: China Biologic Reports Unaudited Financial Results for the Third Quarter of 2017 47
Aug 02, 2017: China Biologic Reports Financial Results for the Second Quarter of 2017 51
May 03, 2017: China Biologic Reports Financial Results for the First Quarter of 2017 55
Feb 23, 2017: China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2016 58
Corporate Communications 62
Aug 13, 2018: China Biologic names Bing Li as new CEO 62
Legal and Regulatory 63
Aug 28, 2018: China Biologic responds to lawsuit filed in Cayman Islands by former Chairman 63
Other Significant Developments 64
Jan 08, 2018: China Biologic Announces Corporate Update 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
China Biologic Products Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
China Biologic Products Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
China Biologic Products Inc, Deals By Therapy Area, 2012 to YTD 2018 8
China Biologic Products Inc, Medical Devices Deals, 2012 to YTD 2018 9
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
China Biologic Products to Raise USD590 Million in Private Placement of Shares 11
Consortium of Investors to Acquire Remaining Shares in China Biologic Products for USD3.9 Billion 13
CCRE Holdings to Acquire Remaining 94.9% Stake in China Biologic Products 15
China Biologic Products Raises Funds through Public Offering of Shares 16
China Biologic Prices Public Offering of Shares for USD73.5 Million 18
China Biologic Prices Public Offering of Shares for USD30 Million 19
China Biologic Products Acquires Remaining 15.3% Stake in Guizhou Taibang Biological Products for USD62.5 Million 21
China Biologic Products Inc, Key Competitors 22
China Biologic Products Inc, Key Employees 23
China Biologic Products Inc, Subsidiaries 24

List of Figures
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
China Biologic Products Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
China Biologic Products Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[China Biologic Products Inc (CBPO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vector Group Ltd.:企業の戦略・SWOT・財務情報
    Vector Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Vector Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Avadel Pharmaceuticals Plc (AVDL):企業の財務・戦略的SWOT分析
    Avadel Pharmaceuticals Plc (AVDL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Arch Pharmalabs Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Arch Pharmalabs Ltd (Arch Pharmalabs) is a healthcare products company that offers pharmaceutical ingredients. The company manufactures, develops and markets active APIs and intermediates to innovator and generic pharmaceutical players. It offers products such as docetaxel anhydrous and trih …
  • Pro Petroleum Inc:企業の戦略的SWOT分析
    Pro Petroleum Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • GamaMabs Pharma SA-製薬・医療分野:企業M&A・提携分析
    Summary GamaMabs Pharma SA (GamaMabs) is a clinical-stage immuno-oncology company developing optimized therapeutic antibodies for the treatment of cancer. Its lead product candidate GM102, is an anti-AMHR2, Emabling engineered humanized mAb product targeting the receptor of anti-Mullerian hormone (A …
  • Regal Hotels International Holdings Ltd.:戦略・SWOT・企業財務分析
    Regal Hotels International Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Regal Hotels International Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Bausch Health Companies Inc (BHC):企業の財務・戦略的SWOT分析
    Bausch Health Companies Inc (BHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Juhl Energy Inc:電力:M&Aディール及び事業提携情報
    Summary Juhl Energy Inc (Juhl Energy), formerly Juhl Wind Inc, specializes in clean and renewable energy. It offers a wide range of clean energy solutions with focus on solar, wind, biomass and natural gas systems. The company helped develop community-based wind farms. It offers comprehensive servic …
  • Oriola-KD Oyj (OKDBV):企業の財務・戦略的SWOT分析
    Oriola-KD Oyj (OKDBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Ardagh Group SA:企業の戦略・SWOT・財務情報
    Ardagh Group SA - Strategy, SWOT and Corporate Finance Report Summary Ardagh Group SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Nissin Electric Co Ltd (6641):企業の財務・戦略的SWOT分析
    Nissin Electric Co Ltd (6641) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Green Plains Inc.:企業の戦略・SWOT・財務情報
    Green Plains Inc. - Strategy, SWOT and Corporate Finance Report Summary Green Plains Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • NIIT Ltd (NIITLTD):企業の財務・戦略的SWOT分析
    NIIT Ltd (NIITLTD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • The New York Times Company (NYT):企業の財務・戦略的SWOT分析
    The New York Times Company (NYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Immusoft Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Immusoft Corp (Immusoft) is a biotechnology start-up company that focuses on the development of autologous cell therapy platform for the treatment of genetic diseases. The company’s technology includes immune system programming (ISP) technology, gene delivery technology and lymphopoiesis cul …
  • USG Corporation:企業の戦略・SWOT・財務情報
    USG Corporation - Strategy, SWOT and Corporate Finance Report Summary USG Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • ION Geophysical Corporation (IO)-石油・ガス分野:企業M&A・提携分析
    Summary ION Geophysical Corporation (ION) is a provider of seismic solutions. It offers advanced seismic data acquisition equipment, software, and seismic processing and planning services to the global oil and gas industry. The company acquires, process and interpret seismic data from seismic survey …
  • Medpace Inc (MEDP):企業の財務・戦略的SWOT分析
    Summary Medpace Inc (Medpace), a subsidiary of Medpace Holdings Inc is a contract research organization that develops research based drug and medical device. The organization provides services such as medical affairs, regulatory affairs and medical writing, clinical monitoring, clinical trial manage …
  • KP Energy Ltd (539686):電力:M&Aディール及び事業提携情報
    Summary KP Energy Ltd (KP Energy) is an alternative energy company that offers power and wind energy solutions. The company provides services such as turnkey solutions, BOT basis services, land acquisition, project development, cost studies, site identification, capacity installations, engineer, pro …
  • ABX Advanced Biochemical Compounds GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary ABX Advanced Biochemical Compounds GmbH (ABX), a subsidiary of Otsuka Holdings Co Ltd is a provider of biochemical compounds that manufactures, develops, and distributes biochemicals for nuclear medicine. The company provides products such as PET and SPECT precursors and reference standards, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆